Artículo
Comprando el artículo el PDF del mismo podrá ser descargado
Precio 19,34 €
Comprar ahora
array:23 [ "pii" => "S0025775317309119" "issn" => "00257753" "doi" => "10.1016/j.medcli.2017.10.041" "estado" => "S300" "fechaPublicacion" => "2018-07-23" "aid" => "4362" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2017" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2018;151:85-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 13 "formatos" => array:2 [ "HTML" => 7 "PDF" => 6 ] ] "itemSiguiente" => array:19 [ "pii" => "S0025775317309156" "issn" => "00257753" "doi" => "10.1016/j.medcli.2017.11.031" "estado" => "S300" "fechaPublicacion" => "2018-07-23" "aid" => "4366" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2018;151:e7-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 21 "formatos" => array:2 [ "HTML" => 15 "PDF" => 6 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Hemopleuropericardio secundario a dabigatrán" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e7" "paginaFinal" => "e8" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Hemorrhagic pleuropericardial effusion secondary to dabigatran" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Iria Sanlés González, Beatriz de Tapia Majado, José Ramón Berrazueta Fernández" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Iria" "apellidos" => "Sanlés González" ] 1 => array:2 [ "nombre" => "Beatriz" "apellidos" => "de Tapia Majado" ] 2 => array:2 [ "nombre" => "José Ramón" "apellidos" => "Berrazueta Fernández" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020618302158" "doi" => "10.1016/j.medcle.2018.05.023" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020618302158?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775317309156?idApp=UINPBA00004N" "url" => "/00257753/0000015100000002/v1_201807060854/S0025775317309156/v1_201807060854/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0025775317309016" "issn" => "00257753" "doi" => "10.1016/j.medcli.2017.11.020" "estado" => "S300" "fechaPublicacion" => "2018-07-23" "aid" => "4352" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2018;151:84-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 10 "formatos" => array:2 [ "HTML" => 6 "PDF" => 4 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta al Editor</span>" "titulo" => "Síndrome de activación macrofágica inducido por administración prolongada de anfotericina-B liposomal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "84" "paginaFinal" => "85" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Macrophage activation syndrome induced by prolonged treatment with liposomal amphotericin B" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1874 "Ancho" => 2500 "Tamanyo" => 725123 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">a y b) Tinción H&E de la biopsia hepática: a) parte del cilindro que, a menor aumento, muestra una arquitectura normal del lóbulo hepático; b) Mayor aumento de «a». Las flechas indican histiocitos con núcleos periféricos y un citoplasma elongado y granular; c y d) menor y mayor aumento de la tinción inmunohistoquímica del CD68 confirmando la presencia de abundantes histiocitos.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Gerhard Jung, Enric Reverter, Javier Fernández" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Gerhard" "apellidos" => "Jung" ] 1 => array:2 [ "nombre" => "Enric" "apellidos" => "Reverter" ] 2 => array:2 [ "nombre" => "Javier" "apellidos" => "Fernández" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020618302146" "doi" => "10.1016/j.medcle.2018.05.022" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020618302146?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775317309016?idApp=UINPBA00004N" "url" => "/00257753/0000015100000002/v1_201807060854/S0025775317309016/v1_201807060854/es/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "85" "paginaFinal" => "86" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Esther Chamorro-de-Vega, Alvaro Gimenez-Manzorro, Maria Sanjurjo" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Esther" "apellidos" => "Chamorro-de-Vega" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 1 => array:4 [ "nombre" => "Alvaro" "apellidos" => "Gimenez-Manzorro" "email" => array:1 [ 0 => "alvaro.gimenez@salud.madrid.org" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 2 => array:3 [ "nombre" => "Maria" "apellidos" => "Sanjurjo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">◊</span>" "identificador" => "fn0005" ] ] ] 3 => array:1 [ "colaborador" => "on behalf of the GRUVIC Study Group" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria del Hospital Gregorio Marañón (IiSGM), Madrid, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Sofosbuvir/ledipasvir para el tratamiento de la infección por genotipo 5 del virus de hepatitis C: descripción de dos casos" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Hepatitis C virus (HCV) infection generates a considerable public health burden and is the major cause of liver disease. HCV genotype 5 is a rare genotype that accounts for about 1.4 million cases.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> However, more recent studies report an unusually high and local prevalence of HCV genotype 5 in Spain, Belgium, and France.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Until 2011, treatment with pegylated interferon and ribavirin was the standard of care for HCV genotype 5 infection, although only 60% of treated patients achieved SVR after 48 weeks of treatment. With the development of direct-acting antivirals (DAAs), international guidelines contemplate sofosbuvir/ledipasvir (SOF/LDV), sofosbuvir/velpatasvir (SOF/VPV), and sofosbuvir<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>daclatasvir (SOF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>DCV) as possible therapy in genotype 5 infection.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">3,4</span></a> Although these regimens have improved the efficacy, safety, and tolerability of HCV treatment, they have been assessed in very few genotype 5 patients. In the case of SOF/LDV, the only results reported are from a phase II clinical trial of patients infected with genotype 5,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a> therefore, evidence regarding the efficacy and safety in this specific population is scarce. We present the first 2 case reports of patients infected with HCV genotype 5 treated with SOF/LDV.</p><p id="par0015" class="elsevierStylePara elsevierViewall">A 61-year-old Caucasian man was diagnosed with biopsy-proven HCV genotype 5 infection in 2006. He had a history of hypertension, benign prostatic hyperplasia, hemoptysis due to bronchiectasis, erosive gastroenteritis, and polyglobulia. He had been treated for HCV infection with pegylated interferon and ribavirin for 48 weeks, with virologic relapse.</p><p id="par0020" class="elsevierStylePara elsevierViewall">In November 2015, the patient's baseline workup revealed a viral load (VL) of 17,340,000<span class="elsevierStyleHsp" style=""></span>IU/ml (7.24 log), fibrosis stage F2 (FibroScan value of 8.8<span class="elsevierStyleHsp" style=""></span>kPa), ALT 36<span class="elsevierStyleHsp" style=""></span>U/l, AST 27<span class="elsevierStyleHsp" style=""></span>U/l, alkaline phosphatase 142<span class="elsevierStyleHsp" style=""></span>U/l, hemoglobin 15.4<span class="elsevierStyleHsp" style=""></span>g/dl, platelet count 114<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">3</span>/μl, bilirubin 0.9<span class="elsevierStyleHsp" style=""></span>mg/dl, and CrCl<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>60<span class="elsevierStyleHsp" style=""></span>ml/min. Concomitant treatment comprised telmisartan/hydrochlorothiazide 80/25<span class="elsevierStyleHsp" style=""></span>mg/d, spironolactone 25<span class="elsevierStyleHsp" style=""></span>mg/d, omeprazole 20<span class="elsevierStyleHsp" style=""></span>mg/d, cabergoline 0.5<span class="elsevierStyleHsp" style=""></span>mg three days per week and intramuscular testosterone 250<span class="elsevierStyleHsp" style=""></span>mg every two months. Oral antiviral treatment was initiated with coformulated SOF/LDV administered once daily at 400/90<span class="elsevierStyleHsp" style=""></span>mg and ribavirin twice daily up to a total daily dose of 1000<span class="elsevierStyleHsp" style=""></span>mg (according to body weight) for 12 weeks. Due to the interaction between LDV and omeprazole, simultaneous administration of both drugs under fasting conditions was recommended. No further changes in treatment were made.</p><p id="par0025" class="elsevierStylePara elsevierViewall">At 4 weeks into treatment, the patient had an undetectable HCV RNA VL. He reported the presence of asthenia, pruritus, and dry skin (all grade 1 according to the CTCAE). Analytic parameters remained normal, except for hemoglobin (decreased from 15.4<span class="elsevierStyleHsp" style=""></span>g/dl to 12.5<span class="elsevierStyleHsp" style=""></span>g/dl) and bilirubin (increased from 0.9<span class="elsevierStyleHsp" style=""></span>mg/dl to 2.3<span class="elsevierStyleHsp" style=""></span>mg/dl), thus leading to a reduction in the dose of ribavirin to 800<span class="elsevierStyleHsp" style=""></span>mg/d. By the end of treatment, HCV RNA VL remained undetectable, and adverse events disappeared, except for asthenia. Hemoglobin values returned to normal (13.3<span class="elsevierStyleHsp" style=""></span>g/dl), although bilirubin remained slightly high (2.0<span class="elsevierStyleHsp" style=""></span>mg/dl). At weeks 12 and 24 after the end of the treatment, VL remained undetectable, and adverse events and laboratory abnormalities gradually improved.</p><p id="par0030" class="elsevierStylePara elsevierViewall">A 56-year-old Caucasian man was diagnosed with HCV genotype 5a in 2006. His medical history was remarkable for Down's syndrome, hepatitis B virus infection, autoimmune primary hypothyroidism and mild chronic kidney failure. The patient had not previously been treated for HCV.</p><p id="par0035" class="elsevierStylePara elsevierViewall">In October 2015, the baseline workup yielded a VL of 154,494<span class="elsevierStyleHsp" style=""></span>IU/ml (5.19 log), fibrosis stage F3 (by biopsy), ALT 41<span class="elsevierStyleHsp" style=""></span>U/l, AST 35<span class="elsevierStyleHsp" style=""></span>U/l, alkaline phosphatase 63<span class="elsevierStyleHsp" style=""></span>U/l, hemoglobin 14.5<span class="elsevierStyleHsp" style=""></span>g/dl, platelet count 160<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">3</span>/μl, bilirubin 0.6<span class="elsevierStyleHsp" style=""></span>mg/dl, CrCl<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>60<span class="elsevierStyleHsp" style=""></span>ml/min, and IL28B genotype CT. His concomitant treatment comprised lamivudine 100<span class="elsevierStyleHsp" style=""></span>mg/d, acyclovir 200<span class="elsevierStyleHsp" style=""></span>mg twice daily, levothyroxine 100<span class="elsevierStyleHsp" style=""></span>μg/d, and autologous serum collyrium. Oral coformulated SOF/LDV (400/90<span class="elsevierStyleHsp" style=""></span>mg) once daily for 12 weeks was initiated without any modification of his concomitant treatment.</p><p id="par0040" class="elsevierStylePara elsevierViewall">At 4 weeks into treatment, the patient had an undetectable HCV RNA VL, and no adverse events or laboratory abnormalities were found. By the end of treatment, HCV RNA VL remained undetectable and no adverse events were reported. Temporary grade 1 elevation of transaminases was observed (ALT 80<span class="elsevierStyleHsp" style=""></span>U/l, AST 47<span class="elsevierStyleHsp" style=""></span>U/l) but returned to normal values (ALT 14<span class="elsevierStyleHsp" style=""></span>U/l, AST 20<span class="elsevierStyleHsp" style=""></span>U/l) at week 20. At weeks 12 and 24 after the end of the treatment, HCV RNA VL remained undetectable, and no virologic rebound of HBV DNA VL was detected during the follow-up.</p><p id="par0045" class="elsevierStylePara elsevierViewall">This is the first case report to corroborate the effectiveness of SOF/LDV for 12 weeks in treatment-naïve and treatment-experienced patients with HCV genotype 5 infection. SOF/LDV has a good safety profile in routine clinical practice.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding source</span><p id="par0050" class="elsevierStylePara elsevierViewall">This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conflicts of interest</span><p id="par0055" class="elsevierStylePara elsevierViewall">Álvaro Giménez Manzorro has participated on advisory boards for MSD and AbbVie. The remaining authors do not have any conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding source" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Conflicts of interest" ] 2 => array:2 [ "identificador" => "xack355719" "titulo" => "Acknowledgments" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:3 [ "etiqueta" => "◊" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Equal contribution.</p>" "identificador" => "fn0005" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global distribution and prevalence of hepatitis C virus genotypes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. Messina" 1 => "I. Humphreys" 2 => "A. Flaxman" 3 => "A. Brown" 4 => "G.S. Cooke" 5 => "O.G. Pybus" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.27259" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "77" "paginaFinal" => "87" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25069599" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Antaki" 1 => "M. Haddad" 2 => "K. Kebbewar" 3 => "J. Abdelwahab" 4 => "O. Hamed" 5 => "R. Aaraj" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1017/S095026880800054X" "Revista" => array:6 [ "tituloSerie" => "Epidemiol Infect" "fecha" => "2009" "volumen" => "137" "paginaInicial" => "79" "paginaFinal" => "84" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18346288" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EASL Recommendations on Treatment of Hepatitis C 2016" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "European Association for the Study of the Liver" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2016.09.001" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2017" "volumen" => "66" "paginaInicial" => "153" "paginaFinal" => "194" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27667367" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "Available at: <a class="elsevierStyleInterRef" target="_blank" id="intr0005" href="http://www.hcvguidelines.org/">http://www.hcvguidelines.org/</a>. Accessed Jun, 2017" "contribucion" => array:1 [ 0 => array:1 [ "titulo" => "Hepatitis C guidance: AASLD-IDSA. Recommendations for testing, managing, and treating adults infected with hepatitis C virus" ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.27950" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2015" "volumen" => "62" "paginaInicial" => "932" "paginaFinal" => "954" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26111063" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infeciton: an open-label, multicentre, single-arm, phase 2 study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Abergel" 1 => "T. Asselah" 2 => "S. Metivier" 3 => "K. Kersey" 4 => "D. Jiang" 5 => "H. Mo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(15)00529-0" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2016" "volumen" => "16" "paginaInicial" => "459" "paginaFinal" => "464" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26803446" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack355719" "titulo" => "Acknowledgments" "texto" => "<p id="par0060" class="elsevierStylePara elsevierViewall">The authors would like to thank Tom O‘Boyle for help with the English language.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/00257753/0000015100000002/v1_201807060854/S0025775317309119/v1_201807060854/en/main.assets" "Apartado" => array:4 [ "identificador" => "66430" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Cartas al Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00257753/0000015100000002/v1_201807060854/S0025775317309119/v1_201807060854/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775317309119?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en este medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
Medicina Clínica, fundada en 1943, es la única publicación semanal de contenido clínico que se edita en España y constituye el máximo exponente de la calidad y pujanza de la medicina española. Son características fundamentales de esta publicación el rigor científico y metodológico de sus artículos, la actualidad de los temas y, sobre todo, su sentido práctico, buscando siempre que la información sea de la mayor utilidad en la práctica clínica. Los contenidos de Medicina Clínica abarcan dos frentes: trabajos de investigación original rigurosamente seleccionados atendiendo a su calidad, originalidad e interés, y trabajos orientados a la formación continuada, encomendados por la revista a autores relevantes (Editoriales, Revisiones, Conferencias clínicas y clínico-patológicas, Diagnóstico y Tratamiento). En estos artículos se ponen al día aspectos de destacado interés clínico o conceptual en la medicina actual. Medicina Clínica es un vehículo de información científica de reconocida calidad, como demuestra su inclusión en los más prestigiosos y selectivos índices bibliográficos del mundo.
Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, ScienceDirect
Ver másEl factor de impacto mide la media del número de citaciones recibidas en un año por trabajos publicados en la publicación durante los dos años anteriores.
© Clarivate Analytics, Journal Citation Reports 2022
SJR es una prestigiosa métrica basada en la idea de que todas las citaciones no son iguales. SJR usa un algoritmo similar al page rank de Google; es una medida cuantitativa y cualitativa al impacto de una publicación.
Ver másSNIP permite comparar el impacto de revistas de diferentes campos temáticos, corrigiendo las diferencias en la probabilidad de ser citado que existe entre revistas de distintas materias.
Ver más¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos